Journal of International Oncology››2018,Vol. 45››Issue (3): 148-156.doi:10.3760/cma.j.issn.1673-422X.2018.03.005
Previous ArticlesNext Articles
Guo Xinwei, Ji Shengjun, Zhou Shaobing, Gu Liang, Liu Yangchen
Received:
2017-08-09Online:
2018-03-08Published:
2018-05-16Contact:
Zhou Shaobing E-mail:zsb633@163.comSupported by:
Guo Xinwei, Ji Shengjun, Zhou Shaobing, Gu Liang, Liu Yangchen. Influences of the size of lymph node metastasis on the chemoradiotherapy efficacy and prognosis for the patients after esophagectomy of thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2018, 45(3): 148-156.
[1] Liu J, Xie X, Zhou C, et al. Which factors are associated with actual 5year survival of oesophageal squamous cell carcinoma?[J]. Eur J Cardiothorac Surg, 2012, 41(3): e7-e11. DOI: 10.1093/ejcts/ezr240. [2] Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy[J]. PLoS One, 2014, 9(5): e97225. DOI: 10.1371/journal.pone.0097225. [3] 苏娜, 王雅棣, 李成林, 等. N0期胸段食管癌GTV长度和最大直径及体积对放疗预后影响[J]. 中华放射肿瘤学杂志, 2014, 23(1): 27-30. DOI: 10.3760/cma.j.issn.1004-4221.2014.01.007. [4] Chen Y, Zhang Z, Jiang GL, et al. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy[J]. J Thorac Dis, 2016, 8(6): 11551161. DOI: 10.21037/jtd.2016.04.08. [5] 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志, 2010, 19(3): 179-180. DOI: 10.3760/cma.j.issn.1004-4221.2010.03.001. [6] Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know[J]. AJR Am J Roentgenol, 2010, 195(2): 281-289. DOI: 10.2214/AJR.09.4110. [7] Chen HL, Wu ZY, Chen JX, et al. Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases[J]. Med Oncol, 2015, 32(1): 10. DOI: 10.1007/s12032-014-0417-6. [8] Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensitymodulated radiotherapy for upper esophageal carcinoma[J]. Radiat Oncol, 2013, 8(1): 75. DOI: 10.1186/1748717X8-75. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[6] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[7] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[8] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[9] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[10] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[11] | Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[12] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[13] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[14] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[15] | Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||